Stockwinners Market Radar for July 05, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:09 EDT Cathie Wood's ARK Investment bought 248.8K shares of Nextdoor today

20:08 EDT Cathie Wood's ARK Investment bought 93.3K shares of Robinhood today

20:07 EDT Enphase begins microinverter shipments from South Carolina with Flex - Enphase Energy (ENPH) announced initial shipments of Enphase IQ(R) Microinverters produced in Columbia, South Carolina by global diversified manufacturer Flex (FLEX). This marks the first production from one of Enphase Energy's three contract manufacturing partnerships in the United States, helping to meet the strong global demand for Enphase's products. The Inflation Reduction Act has enabled Enphase Energy to begin manufacturing in the United States, creating new jobs, advancing the country's clean energy economy, and contributing to the growth of the Company's business.

19:00 EDT Marathon Digital reports June bitcoin production up 599% from last year - The company states: "We produced 979 bitcoin in June, down 21% from last month and up 599% from June 2022. The decreased production relative to last month was due to weather-related curtailment in Texas and a significant decrease in transaction fees, which fell to approximately 5.1% of the total bitcoin we earned in June compared to 11.8% in May. The emergence of Ordinals significantly increased transaction fees in May, and while network congestion eased in June, we view recent trends as a positive sign for the future of mining economics. In June, we increased our operational hash rate 16% month-over-month to 17.7 exahashes, and we increased our installed hash rate 8% month-over-month to 21.8 exahashes. The final steps to achieving our 23 EH/s goal are in Ellendale, ND and Garden City, TX. The final building in Ellendale is expected to come online this month, and final Garden City tie in is also expected within that same period. In addition, we are also excited to announce that our new joint venture in Abu Dhabi began hashing earlier this week as the first containers in our Mina Zayed facility powered up. The speed of execution from ideation to production is a testament to Marathon's significant technology expertise and our growing team of mining professionals. Our UAE partners at Zero Two have quickly brought our combined vision to reality, and we continue to expect the full 7.0 exahashes to be online before year end 2023. Note despite this progress, the reported operational hash rate of 21.8 exahashes and 23 exahash guidance remain exclusive of the JV."

18:16 EDT Nymox delisting from Nasdaq - Nymox received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the company's shares will be suspended from trading on Nasdaq at the open of business on July 7. Nymox shares will be moved to the OTC market. Nymox is in the process of submitting applications for the approval to market the company's first in class drug Nymozarfex to treat the symptoms of benign prostatic hyperplasia. Nymozarfex was submitted to the Danish authorities in December 2022 and the application is currently undergoing review. Another submission for approval in another jurisdiction is expected to be submitted in the near future.

17:58 EDT Regeneron gets FDA orphan drug designation for cemdisiran - According to a post on the FDA's website, Regeneron's cemdisiran was granted orphan designation in treatment of Myasthenia Gravis. Reference Link

17:31 EDT Asur reports June passenger traffic up 4.5% from last year - Asur "announced that passenger traffic for June 2023 reached a total of 5.9 million passengers, 4.5% above the levels reported in June 2022. Passenger traffic increased 10.3% year-on-year in Mexico and 22.3% in Puerto Rico, while it decreased 19.8% in Colombia. Passenger traffic growth in Mexico and Puerto Rico was mainly driven by domestic traffic, which increased 19.0% and 20.5%, respectively. This was further supported by growth in international traffic of 3.0% and 36.4%, respectively. Passenger traffic in Colombia was negatively affected by the suspension of operations of two local airlines since March 2023."

17:06 EDT Axon promotes Brittany Bagley to COO role - The company states: "On June 28, 2023, the company promoted Brittany Bagley to COO and CFO effective immediately. Ms. Bagley joined as the Company's Chief Financial Officer and Chief Business Officer in September 2022. As COO and CFO, Ms. Bagley will be responsible for further integrating Axon's financial functions with its operations, including manufacturing and supply chain, and driving operational improvements to contribute to the strength of Axon's income statement, balance sheet and statement of cash flows, including through more streamlined management of cost of goods sold, inventory and working capital."

16:56 EDT Abcam sees first-half revenue up 10% - The company states: "First half 2023 estimated revenues grew approximately 10% on a reported basis or 5.5% on a constant exchange rate basis as compared to 20% growth on a constant exchange rate basis in the comparable prior period. Adjusted operating profit margin is up by approximately 300 basis points to greater than26% for the half. Total revenue and adjusted operating profit are trending in-line with first half and full year 2023 Board expectations. The company continues to see improvements in transactional Net Promoter Score, exiting H1 at +37 for June."

16:43 EDT Monolithic Power CEO sells $5.89M in common stock - In a regulatory filing, Monolithic Power disclosed that its CEO Michael Hsing sold 11K shares of common stock on July 3rd in a total transaction size of $5.89M.

16:39 EDT JetBlue to turn 'even more focus' on Spirit combination after NEA termination - JetBlue (JBLU) issued the following statement regarding its Northeast Alliance, NEA, with American Airlines (AAL): The statement said in part: "JetBlue's unique model has successfully disrupted the industry for well over 20 years, and we decided to enter into the NEA as a creative solution to bring more of the JetBlue Effect to customers in New York and Boston, where our growth has been challenged by constraints outside of our control. By all measures, it succeeded. As a direct result of the NEA, customers benefitted from more of JetBlue's low-fare, high-quality service than ever. We've increased capacity, added new routes and destinations, brought down fares, provided JetBlue-American flight connections that are a real alternative to Delta (DAL) and United (UAL), and expanded the value of our loyalty program benefits to customers. For these reasons, we strongly disagree with the court's ruling against the NEA and stand behind the procompetitive impact of the alliance. We will now turn even more focus to our proposed combination with Spirit (SAVE), which is the best and most effective opportunity to truly transform the competitive landscape in the U.S. and bring the JetBlue Effect to more routes and markets across the country. As it relates to the Spirit combination, terminating the NEA renders the U.S. Department of Justice's, DOJ, concerns about our partnership with a legacy carrier entirely moot. ...The DOJ's proposal is too onerous and overreaching, ignoring arguments the DOJ itself presented at trial about the benefits of similar aspects of other domestic carrier partnerships. With strong momentum, a clear organic plan, and the procompetitive Spirit combination on the horizon, we are ready to be a force for good in the industry on a more national scale and look forward to advancing our planned combination with Spirit." Reference Link

16:36 EDT L.B. Foster sells concrete rail tie operations - L.B. Foster's CXT subsidiary has completed the sale of substantially all the operating assets of its prestressed concrete railroad tie business located in Spokane, WA to voestalpine Railway Systems Nortrak. The company is retaining all pre-closing accounts receivable and liabilities associated with the business, while the asset sale to Nortrak includes all owned inventory associated with the line of business, as well as the related fixed assets. Total cash proceeds from the transaction are expected to be approximately $3M, subject to customary working capital adjustments. Revenues from the divested business, which was part of the company's Rail, Technologies, and Services segment, totaled approximately $9M for the trailing-twelve-months ended June 30. The completed transaction did not have a material impact on the company's financial guidance for its fiscal year 2023. The company expects net sales for 2023 to range between $520M-$550M, with adjusted EBITDA expected between $27M-$31M.

16:34 EDT InnovAge appoints Ben Adams as CFO - InnovAge named Ben Adams its CFO, effective July 10. Barb Gutierrez steps down from the role of CFO to explore new career opportunities. Adams most recently served as CFO of Kepro, a physician-led, technology-enabled company that facilitates care for priority populations to help them remain in the home or community of their choice. Prior to Kepro, Adams served as CFO of RxSense, which provides direct to consumer pharmacy discount programs and B2B technology solutions to a broad range of pharmacy benefit providers. Earlier in his career, Adams was a senior health care investment banker for more than two decades.

16:29 EDT Emcor CEO sells $1.43M in common stock - In a regulatory filing, Emcor disclosed that its CEO Anthony Guzzi sold 7.7K shares of common stock on June 30th in a total transaction size of $1.43M.

16:17 EDT Enact Holdings in quota share reinsurance pact with 'broad panel' of reinsurers - Enact Holdings announced that its flagship legal entity, Enact Mortgage Insurance Corporation, has entered into a quota share reinsurance agreement with a broad panel of highly rated reinsurers. Under the agreement, and subject to certain conditions, Enact will cede 13.125% of a portion of current and expected new insurance written for the period from January 1, through December 31 . "We're very pleased to have entered into this quota share agreement, said Rohit Gupta, President and CEO of Enact. "This agreement builds on the success of our CRT program and reflects the ongoing execution of our strategy and continued commitment to pursuing high-quality new business while driving capital efficiency and minimizing credit risk. It is another step in creating long-term value for our shareholders and advancing our mission to responsibly help more people become homeowners.

16:15 EDT Histogen pauses further program development to explore strategic alternatives - Histogen announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs and commence a process to explore strategic alternatives with the intent to enhance shareholder value. Histogen has engaged Roth Capital Partners to act as a strategic advisor in this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sale of assets, financing alternatives, licensing, or other strategic transactions involving the company. There can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The company does not intend to make any further disclosures regarding the strategic review process unless and until a specific course of action is approved by the company's Board of Directors or until the company determines that further disclosure is appropriate. "We remain excited about emricasan given its broad potential to treat both viral and bacterial infections as a more generalized host-based immunotherapeutic treatment without the risk of generating resistance," said Steven J. Mento, Ph.D., President and Chief Executive Officer. "However, we have paused our development activities in order to preserve our remaining resources and extend our cash runway to explore strategic alternatives that have the potential to benefit shareholders" added Dr. Mento.

16:11 EDT Lyell Immunopharma says Matthew Lang, J.D. has joined as Chief Business Officer - Lyell Immunopharma announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer. In this newly created role, Mr. Lang will serve on Lyell's executive committee and will be responsible for Lyell's legal, compliance, human resources, alliance management and early commercialization teams. He will also serve as Lyell's Chief Legal Officer and Corporate Secretary. "Matt is an experienced company builder who has successfully led growth in complex organizations to realize the value of innovative medicines for patients and shareholders," said Lynn Seely, M.D., Lyell's President and CEO. "I am delighted to welcome him to the team as we advance our mission of unlocking the potential of cell therapy for patients with solid tumors."

16:09 EDT Nikola announces $41.9M grant with sponsor Caltrans - Nikola announced that the California Transportation Commission has awarded Nikola and sponsor California Department of Transportation, or Caltrans, a $41.9M grant under the Trade Corridor Enhancement Program to build six heavy-duty hydrogen refueling stations across Southern California. Caltrans sponsored the application and will work in partnership with Nikola to deploy the tranche of six hydrogen refueling stations, the company said in a statement.

16:07 EDT JetBlue initiates termination of Northeast Alliance with American Airlines - JetBlue (JBLU) issues statement regarding its Northeast Alliance with American Airlines (AAL), stating: "JetBlue's unique model has successfully disrupted the industry for well over 20 years, and we decided to enter into the NEA as a creative solution to bring more of the JetBlue Effect to customers in New York and Boston, where our growth has been challenged by constraints outside of our control. By all measures, it succeeded. As a direct result of the NEA, customers benefitted from more of JetBlue's low-fare, high-quality service than ever. We've increased capacity, added new routes and destinations, brought down fares, provided JetBlue-American flight connections that are a real alternative to Delta and United, and expanded the value of our loyalty program benefits to customers. For these reasons, we strongly disagree with the court's ruling against the NEA and stand behind the procompetitive impact of the alliance. Despite our deep conviction in the procompetitive benefits of the NEA, after much consideration, JetBlue has made the difficult decision not to appeal the court's determination that the NEA cannot continue as currently crafted, and has instead initiated the termination of the NEA, beginning a wind down process that will take place over the coming months. We will now turn even more focus to our proposed combination with Spirit, which is the best and most effective opportunity to truly transform the competitive landscape in the U.S. and bring the JetBlue Effect to more routes and markets across the country. As it relates to the Spirit combination, terminating the NEA renders the U.S. Department of Justice's (DOJ) concerns about our partnership with a legacy carrier entirely moot. With that, the DOJ should reconsider and support our plan to bring a national low-fare competitor to the Big Four; the flying public deserves better than the status quo. The DOJ itself has acknowledged the benefits of JetBlue's disruptive impact on the industry, and we are open to working with the DOJ to address any remaining concerns they have. The NEA is a complex partnership with many thousands of customers who have already booked travel in the months ahead. For customers, it's important to note that nothing will change immediately and they can feel confident in new and existing bookings for the coming months. In addition, customers can continue to earn/redeem points and receive reciprocal loyalty benefits. We will continue to work through the legal process to achieve a wind down plan that protects consumers, and look forward to presenting our view to the court in the coming weeks. The DOJ's proposal is too onerous and overreaching, ignoring arguments the DOJ itself presented at trial about the benefits of similar aspects of other domestic carrier partnerships."

16:07 EDT Nikola awarded $41.9M grant for hydrogen refueling stations - Nikola announced that the California Transportation Commission has awarded Nikola and sponsor California Department of Transportation a $41.9M grant under the Trade Corridor Enhancement Program to build six heavy-duty hydrogen refueling stations across Southern Calif. Caltrans sponsored the application and will work in partnership with Nikola to deploy the tranche of six hydrogen refueling stations.

16:06 EDT Nkarta appoints Alyssa Levin as Chief Financial and Business Officer - Nkarta announced the appointment of Alyssa Levin as Chief Financial and Business Officer. "Alyssa is a results-oriented leader with substantial financial and transaction experience, a proven track record of driving business transformation, and strong drug development knowledge that will be essential as we continue to advance our pipeline of groundbreaking NK cell therapies," said Paul J. Hastings, President and CEO of Nkarta. "We are excited to have Alyssa join our leadership team and look forward to leveraging her expertise as we prioritize activities that support the acceleration of our two lead programs, NKX101 and NKX019, closely manage our cash resources, and augment our growth by managing current partnerships and assessing new ones."

16:03 EDT Merus granted Breakthrough Therapy Designation for zenocutuzumab - Merus announced that the FDA has granted Breakthrough Therapy Designation, or BTD, for zenocutuzumab for the treatment of patients with advanced unresectable or metastatic NRG1 fusion, or NRG1+, non-small cell lung cancer, or NSCLC, following progression with prior systemic therapy. This designation for Zeno follows BTD for the treatment of patients with NRG1+ pancreatic cancer, following progression with prior systemic therapy or in patients who have no satisfactory alternative treatment options recently announced on June 30, Fast Track Designation for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions that have progressed on standard of care therapy announced in January 2021 and Orphan Drug Designation for the treatment of patients with pancreatic cancer announced in July 2020.

16:01 EDT CBIZ acquires American Pension Advisors - CBIZ announced that it has acquired American Pension Advisors, Ltd. of Indianapolis, IN, effective July 1. Founded in 1997, APA provides full-service retirement plan consulting and administration assisting more than 1,200 clients in the design, implementation, and administration of all types of retirement plans including 401(k), 403(b), 457(b), defined benefit and cash balance. APA has 14 employees and approximately $2.9M in revenue.

14:18 EDT Worthington CFO Hayek sells $1.5M in company shares - The CFO of Worthington Industries Joseph Hayek disclosed the sale of 21,100 shares of company stock at $68.95 per share on June 30, for a total transaction amount of $1,454,771.

14:05 EDT TD Synnex CEO Hume sells $1.4M in company shares - The CEO of TD Synnex Richard Hume disclosed the sale of 15,000 shares of company stock at $92.61 per share on July 3, for a total transaction amount of $1,389,155.

13:01 EDT 26 Capital says Tiger Resorts Asia purported notice of termination 'baseless' - 26 Capital Acquisition Corp. confirms that on June 30 it received a purported notice of termination of the Agreement and Plan of Merger and Share Acquisition, dated as of October 15, 2021, from Tiger Resorts Asia Ltd. "26 Capital believes that the termination notice is baseless. 26 Capital believes that Tiger Resorts and its affiliates have engaged in repeated contractual breaches to avoid closing, which is the subject of a pending Delaware litigation going to trial on July 10, 2023. 26 Capital refers to the public docket for the litigation for background on the Tiger Resorts allegations, which 26 Capital believes are meritless. 26 Capital is eager to commence trial on July 10, 2023 and remains fully committed to closing the transaction and improving the merged company's corporate governance," the company stated.

12:17 EDT WWE: Money in the Bank sets record for highest-grossing arena event - WWE announced that Money In The Bank, which emanated from The O2 in London on Saturday, became the most-successful and highest-grossing Money In The Bank of all-time. WWE said: "Notably, Money In The Bank set a new record for highest-grossing arena event in WWE history and Friday Night SmackDown from The O2 became the highest-grossing SmackDown of all-time. The weekend generated a combined gate of more than $5.4M." Money In The Bank also set new records for viewership, sponsorship, merchandise and social media, WWE said.

12:00 EDT Osisko Gold falls -12.0% - Osisko Gold is down -12.0%, or -$1.88 to $13.85.

12:00 EDT Wallbox rises 10.9% - Wallbox is up 10.9%, or 39c to $3.97.

12:00 EDT Wolfspeed rises 17.1% - Wolfspeed is up 17.1%, or $9.71 to $66.45.

11:16 EDT Co-Diagnostics settles with SEC over charges of 'misleading' releases - The Securities and Exchange Commission announced that it deems it appropriate that cease-and-desist proceedings be, and hereby are, instituted against Co-Diagnostics and in anticipation of the institution of these proceedings, the respondent has submitted an offer of settlement, which the Commission has determined to accept. "These proceedings concern Co-Diagnostics's issuance of misleading press releases on February 6 and 10, 2020 concerning a screening test it had developed to detect the novel coronavirus, later named COVID-19 by the World Health Organization. Specifically, the press releases misleadingly suggested that the test could be used by consumers to detect COVID-19, when in fact, at that time, the test was intended for Research Use Only, which meant it could not be sold for clinical diagnostic purposes. Co-Diagnostics offered and sold securities to investors after it issued the February 6 and 10, 2020 press releases. In addition, Co-Diagnostics failed to disclose related party transactions involving the family members of the company's Chief Executive Officer and then-Chief Financial Officer, Secretary, and General Counsel in its annual reports for the fiscal years ended December 31, 2018, 2019, and 2020 and in its definitive proxy statements filed in 2019, 2020, and 2021," the SEC stated. Reference Link

11:01 EDT Alignment Health Plan enters agreement with Tucson Medical Center - Alignment Health Plan is expanding access to quality health care and services for its members in Pima and Santa Cruz counties through a new agreement with Tucson Medical Center. Effective July 1, the agreement will provide Alignment's Arizona plan members access to approximately 165 providers and TMC services.

10:52 EDT LiveOne reports 75,000 new members in June - LiveOn has broken multiple membership records and finished June 30th at 3.2M Members, up 33% from Prior Year. Contributing to this surge is Tesla, who achieved a record-breaking delivery of over 466K cars through June and raised their yearly guidance to 2.4 million cars.

10:34 EDT Toyota reports June U.S. sales up 14.9% to 195,448 vehicles - Toyota Motor North America reported U.S. sales in June of 195,448 vehicles, up 14.9% on a volume and daily selling rate, or DSR, basis versus June 2022. June 2023 sales of electrified vehicles totaled 51,535, representing 26.4% of total monthly sales. For the first half of 2023, TMNA reported U.S. sales of 1,038,520 vehicles, down 0.7% on a volume and DSR basis. First half electrified vehicle sales totaled 270,476, representing 26.0 percent of total year-to-date sales.

10:11 EDT Pratt & Whitney engines selected to power A310neo aircraft for Viva Aerobus - Pratt & Whitney, an RTX (RTX) business, announced that Viva Aerobus has selected GTF engines to power an additional 90 Airbus (EADSY) A321neo firm aircraft orders, the first of which is expected to be delivered in 2027. Having previously ordered 65 GTF-powered A320neo family aircraft, the airline has now committed to 155 aircraft with GTF engines. Pratt & Whitney and Viva Aerobus have also extended their EngineWise Maintenance long-term agreement to cover the maintenance needs of the entire GTF-powered fleet.

10:00 EDT Wabash falls -10.1% - Wabash is down -10.1%, or -$2.62 to $23.36.

10:00 EDT Osisko Gold falls -12.0% - Osisko Gold is down -12.0%, or -$1.89 to $13.84.

10:00 EDT Doma Holdings rises 7.1% - Doma Holdings is up 7.1%, or 34c to $5.15.

09:56 EDT Biodexa Pharmaceuticals PLC-ADR trading resumes

09:48 EDT Allarity announces initial data from Phase 2 trial of IXEMPRA - Allarity Therapeutics announced initial results from its European Phase 2 clinical trial evaluating the efficacy of IXEMPRA in metastatic breast cancer patients selected with the DRP-IXEMPRA companion diagnostic candidate. Researchers prescreened mBC patients using Allarity's DRP-IXEMPRA CDx, a complex transcriptomic signature comprising multiple mRNA biomarkers of drug response/resistance. Patients were assigned a DRP-score, and those with scores above 67% were selected for treatment with IXEMPRA. Of the 36 patients screened with the DRP-IXEMPRA CDx, investigators identified five DRP positive patients. Among the evaluable patients assessed up to the data evaluation cut-off, there were promising signs of clinical benefit in four out of four evaluable cases: One partial responder. One partial responder. One patient experienced 24 weeks of stable disease. One patient experienced 19 weeks of stable disease. The study is in a very early stage of an ongoing open-label, single-arm trial, at multiple sites in Europe, evaluating the anti-tumor effect of IXEMPRA in patients with locally recurrent or metastatic breast cancer after previous chemotherapies, including a taxane and an anthracycline. The included patients received a maximum of three prior lines of chemotherapies in the metastatic setting. Allarity recently amended the clinical trial protocol, lowering the DRP cut-off score in order to include more likely responder patients while still excluding those unlikely to respond to the drug. The ultimate objective is to further refine the DRP-IXEMPRA CDx criteria and broaden the enrollment of mBC patients who may substantially benefit from this treatment. The Company anticipates an additional interim data readout before the end of this year.

09:47 EDT BorgWarner falls -10.2% - BorgWarner is down -10.2%, or -$5.11 to $44.81.

09:47 EDT Transocean rises 6.1% - Transocean is up 6.1%, or 42c to $7.39.

09:47 EDT Wolfspeed rises 22.5% - Wolfspeed is up 22.5%, or $12.76 to $69.50.

09:45 EDT Allarity Therapeutics Inc trading halted, volatility trading pause

09:25 EDT Cassava says oral simufilam slowed cognitive decline in withdrawal trial - Cassava Sciences announced top-line clinical results from its Cognition Maintenance Study. The CMS is a small proof-of-concept study designed to demonstrate the effects of drug versus placebo in a randomized withdrawal trial design. The study enrolled 157 patients with mild-to-moderate Alzheimer's disease, a more advanced and difficult-to-treat stage of disease. In this double-blind, placebo-controlled, randomized study, all patients first received open-label simufilam 100 mg for 12 months; patients were then randomized to receive either simufilam 100 mg or placebo for 6 months. 16 U.S. clinical sites participated. The CMS had one pre-specified cognitive endpoint: mean change in ADAS-Cog11 scores over 6 months, drug versus placebo. Simufilam treatment for 6 months slowed cognitive decline by 38% compared to placebo in mild-to-moderate Alzheimer's disease. The placebo arm declined 1.5 points on ADAS-Cog, and this arm declined at all measured timepoints. The simufilam arm declined 0.9 points on ADAS-Cog, a 38% difference in favor of drug at month 6. Upon randomization into the CMS, mean baseline MMSE scores were 18.6 and 18.1 for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores were 19.3 and 21.9 for the simufilam and placebo arms, respectively. Simufilam treatment for 6 months slowed cognitive decline greater than 200% compared to placebo in mild Alzheimer's disease. CMS patients with mild Alzheimer's on placebo declined 0.6 points on ADAS-Cog over 6 months as a group. CMS patients with mild Alzheimer's on simufilam improved 0.6 points over 6 months as a group, a 205% difference in favor of drug. Upon randomization into the CMS, mean baseline MMSE scores for mild patients were MMSE 24.0 and MMSE 24.1 for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores for mild patients were 11.0 and 11.2 for the simufilam and placebo arms, respectively. After taking open-label simufilam for 12 months, 76 patients with mild Alzheimer's disease enrolled in the CMS and were randomized to receive either simufilam or placebo for 6 months. Mild patients randomized to simufilam in the CMS showed no material decline in ADAS-Cog scores over 18 months as a group, indicating stable cognition. Mild patients randomized to placebo in the CMS declined by 0.8 points in ADAS-Cog as a group. Simufilam 100 mg twice daily was safe and well tolerated in this study. There were no drug-related serious adverse events. No treatment-emergent adverse events occurred in 5% or more of study participants in the CMS. The CMS was a randomized withdrawal study. Patients who completed 12 months of open-label simufilam treatment were all invited to participate in the CMS. It is not known how long a washout period may be needed to remove lingering drug effects, if any, from prior treatment with open-label simufilam for 12 months. In this small study of oral simufilam in patients with mild-to-moderate Alzheimer's disease, the pre-specified cognitive endpoint showed a 38% decline in ADAS-Cog over six months in favor of simufilam, with good drug safety. Effects were pronounced in mild patients. Mean baseline MMSE and ADAS-Cog scores were approximately balanced given the small size of each arm.

09:20 EDT Cipher Mining mines 360 bitcoin in June - In June, Cipher continued to expand operations at its Odessa facility and finished June with the potential to mine up to 17.1 bitcoin per day. "The month of June featured challenging operating conditions. Texas experienced record high temperatures, weak wind production and record demand for power as we entered the critical 4CP summer months," said Tyler Page, CEO of Cipher. "Against this backdrop, we are delighted to announce production numbers that reflect not only our ability to navigate tough operating conditions and manage our mining fleet during extreme temperatures, but also our optimization of production through power sales. In this month's report, we introduced a Power Sales Equivalent BTC line item that is not included in our BTC Mined statistic and is an estimate of our incremental power sales for the month expressed in bitcoin terms. We hope this provides insight into our monthly revenue potential beyond just our bitcoin production. With the extreme demand for power in June, we also saw our Odessa PPA counterparty use a significant amount of their annual curtailment budget, which demonstrates the value of bitcoin mining as an industry in supporting the grid at its most vulnerable times and positions us well for the remainder of 2023 if market power prices remain high. As we continue to expand our mining capacity, we aim to deliver operational excellence, even in the hot Texas summer. Our team focuses on efficient optimization of the portfolio, whether that is through the mix of rigs in use, underclocking our machines, or selling power back to the grid at the most valuable times. We are also pleased to announce that we have taken delivery of all 11,000 Canaan rigs that we recently purchased. And with the final build out of the infrastructure in the next few months, we are well on track to deliver on our goal of 7.2 EH/s by the end of Q3."

09:19 EDT Scilex reports June net sales $4.2M-$5.2M vs. $3.3M last year - Scilex Holding Company (SCLX), a majority-owned subsidiary of Sorrento Therapeutics (SRNE) announces revenue for the month of June 2023 and is providing certain preliminary unaudited financial results for the month ended June 30, 2023, quarter ended June 30, 2023, and year-to-date as of June 30, 2023, based on currently available information. The Company estimates that: ZTlido gross sales for June 2023 were in the range of $13.5M to $14.5M, compared to $7.4M in June 2022, representing growth in the range of 82% to 96%; the quarter ended June 2023 were in the range of $37.5M to $39M, compared to $21M for the quarter ended June 2022, representing growth in the range of 79% to 86%; and year-to-date June 2023 were in the range of $64.2M to $67.3M, compared to $39.4M for year-to-date June 2022, representing growth in the range of 63% to 71%. Scilex is well positioned to continue its growth over the next several years. ZTlido net sales for June 2023 were in the range of $4M to $5.1M, compared to $3.3M in June 2022, representing growth in the range of 21% to 54%; the quarter ended June 2023 were in the range of $11.2M to $13.6M, compared to $7.9M for the quarter ended June 2022, representing growth in the range of 42% to 72%; and year-to-date June 2023 were in the range of $20.5M to $23M, compared to $14.7M for year-to-date June 2022, representing growth in the range of 39% to 56%. Total product gross sales for June 2023 were in the range of $14M to $15M, compared to $7.4M in June 2022, representing growth in the range of 89% to 103%; the quarter ended June 2023 were in the range of $39M to $40M, compared to $21M for the quarter ended June 2022, representing growth in the range of 86% to 90%; and year-to-date June 2023 were in the range of $65.6M to $69M, compared to $39.4M for year-to-date June 2022, representing growth in the range of 66% to 75%. Scilex believes the year-to-date gross sales will reflect in the range of $140M to $150M annualized run rate. Total product net sales for June 2023 were in the range of $4.2M to $5.2M, compared to $3.3M in June 2022, representing growth in the range of 27% to 57%; the quarter ended June 2023 were in the range of $12M to $14M, compared to $7.9M for the quarter ended June 2022, representing growth in the range of 52% to 77%; and year-to-date June 2023 were in the range of $20.8M to $24.0M, compared to $14.7M for year-to-date June 2022, representing growth in the range of 41% to 63%.

09:13 EDT Franklin Electric president of global water Donald Kenney to retire - Franklin Electric (FELE) announced that Donald Kenney, Vice President and President, Global Water, will be retiring after 25 years with the company. He will remain with the company through the end of July to ensure a smooth transition to his successor, Greg Levine. Levine will join Franklin Electric on July 3 from Nidec Corporation (NJDCY), where he served as President of the Motion Control and Drives business for the past six years. In his new role, Levine will be responsible for Franklin Electric's global Water Systems business.

09:11 EDT Knight-Swift drops 2% after Q2 warning on 'soft demand'

09:07 EDT STMicroelectronics reveals FlightSense multi-zone distance sensor - STMicroelectronics has revealed a new FlightSense multi-zone distance sensor with 90 degrees field of view - the industry's best and 33% larger than the previous generation. The optical sensors bring lifelike situational awareness to applications like home automation, domestic appliances, computers, robots, and smart equipment used in stores, factories, and more.

09:06 EDT Gatos Silver announces revocation of management cease trade orders - Gatos Silver announced that, effective July 4, 2023, the Ontario Securities Commission fully revoked the management cease trade orders previously granted in respect of certain former and current senior officers of the Company on April 1, 2022, April 12, 2022 and July 7, 2022.

09:06 EDT Sorrento Therapeutics announces Phase IIa sudy results of abivertinib - Sorrento Therapeutics announced results from a China phase IIa study of Abivertinib on R/R MZL and its plan for a pivotal study. Abivertinib is a pyrrolopyrimidine-based, mutant EGFR and BTK dual inhibitor with potential across multiple indications. BTK inhibitors are a large category in cancer treatment, with multiple indications and generating over $10.6 billion per year revenue in 2022. Abivertinib inhibits BTK with IC50 value of 0.4 nM. Previously, a positive phase Ib study result of Abivertinib on B cell lymphoma was reported.The phase IIa study on R/R MZL, a rare type of B cell lymphoma, was conducted in China in 27 R/R MZL patients. Abivertinib showed significant treatment benefits in 27 patients who were relapsed or refractory after multiple lines of treatment with an ORR of 59.3%. This ORR is higher than the ORR of Ibrutinib, which was first approved for the treatment of R/R MZL The DCR was 92.6% and to date, both PFS and DOR have not been reached. In the phase IIa study, Abivertinib was well-tolerated, and no severe bleeding, arrhythmia or hypertension were seen in these Abivertinib-treated patients. Given these early results, Abivertinib has a promising safety and efficacy profile to date, which has the potential for it to be preferable to the approved drug Ibrutinib. Sorrento has communicated with the NMPA, and a consensus has been reached for a pivotal phase III registration study for the treatment of R/R MZL. The pivotal study will be a multicenter phase III study to assess the efficacy and safety of Abivertinib for treatment of relapsed/refractory marginal zone lymphoma. Sorrento will continue communicating with the NMPA to finalize the phase III protocol.

09:05 EDT CF Bankshares announces stock repurchase program - CF Bankshares announced that the Board of Directors of CF Bankshares has authorized a new stock repurchase program pursuant to which the Company may repurchase up to 250,000 shares of the Company's outstanding common stock on or before June 30, 2024. Under the stock repurchase program, the Company may purchase shares of its common stock from time to time through various means, including open market transactions and privately negotiated transactions. Timothy O'Dell, President and CEO, commented "We believe our stock is a good value, and the Board's approval of this stock repurchase program reflects confidence in our Company's intrinsic value. Repurchasing stock underscores our commitment to enhancing shareholder value and demonstrates confidence in our business model."

09:02 EDT Superior Group announces passing of chairman emeritus Gerald Benstock - Superior Group of Companies announced that Gerald Benstock, Chairman Emeritus of the Board of Directors, passed away on June 30, 2023 at the age of 93. Benstock joined SGC in 1951 as an industrial engineer after graduating from night school at New York University.

08:59 EDT Ormat Technologies, SDCP sign long-term power purchase agreement - Ormat Technologies and San Diego Community Power announced the signing of an agreement that will bring clean, renewable, and affordable energy to the nearly 1 million customers of SDCP. Ormat and SDCP signed a power purchase agreement for the Arrowleaf Solar and Storage Facility demonstrating their collective commitments to delivering clean and reliable energy solutions. The Arrowleaf Solar and Storage Facility is located in Imperial County, California, adjacent to Ormat's operational Brawley geothermal facility and within the Imperial Irrigation District service territory. Under the terms of the 20-year contract, Ormat will provide SDCP with sustainable electricity generated by the Arrowleaf Solar and Storage Facility at predictable rates for customers. Operations are expected to commence in the first half of 2025.

08:57 EDT Brera enters definitive agreement to acquire majority stake in Uyba Volley - Brera Holdings executed the definitive agreements related to the acquisition of a majority ownership stake in the Italian Serie A1 women's professional volleyball team UYBA Volley, based in Busto Arsizio, north of Milan. The closing of the acquisition is subject to customary closing conditions contained in the definitive agreements. Under the executed definitive agreements, Brera Holdings will acquire 51% of the share capital of UYBA Volley.

08:55 EDT Altamira Therapeutics enters collaboration, option agreement with Heqet - Altamira Therapeutics has entered into a collaboration and option agreement with Heqet Therapeutics utilizing the Company's proprietary OligoPhore delivery platform. Based in Turin, Italy, Heqet is a biotech spin-out from King's College London. It is developing groundbreaking genetic medicines to reverse the damage of ischemic heart disease. Under the terms of the agreement, Heqet will test nanoparticles based on Altamira's OligoPhore delivery platform and comprising certain non-coding RNAs in the regeneration of damaged heart tissue following myocardial infarction in animal models. Upon successful conclusion of the experiments, Heqet will, under certain conditions, have the option to negotiate with Altamira for a license to use the Company's technology and intellectual property to translate its findings into the development of therapeutics for cardiac regeneration.

08:54 EDT Inter&Co announces new senior management structure - Inter&Co announces a new senior management structure that will enable the Company to be better prepared to continue succeeding in the future. Alexandre Riccio de Oliveira becomes Senior Vice President of Retail Banking, overseeing all the retail banking businesses, including Operations, Clients, Payroll & Real Estate, Insurance, Investments and Credit Underwriting, led by Ray Chalub, Priscila Salles, Flavio Queijo, Paulo Padilha, Felipe Bottino and Mauro Rangel, respectively. Additionally, Amanda Ferracini will be seconded from Softbank to Inter to fulfill the functions of interim Head of Data & Analytics, focusing on leveraging the use of big data and artificial intelligence, reporting to Alexandre. Alexandre has been at Inter since 2013 and has been instrumental in transforming Inter's operational and tech platform to enable the success of the Super App. Santiago Stel becomes Senior Vice President of Finance and Risks, overseeing matters related to Strategy & Financial Planning, Risks Management, Accounting, Treasury, Legal and Research, led by Helena Caldeira, Thiago Garrides, Janderson Facchin, Leonardo Paixao, Ana Luiza Franco and Rafaela Vitoria, respectively. Santiago joined Inter in April 2022 as Chief Strategy and Investor Relations Officer. Joao Vitor Menin will continue defining Inter's vision for the next years and will lead the innovation agenda of the company. In addition to having Alexandre Riccio and Santiago Stel as direct reports, he will continue leading directly matters regarding Digital Commerce, Marketing & Branding, IT, SME & Corporate Financing, HR and the US Operations, led by Rodrigo Gouveia, Andrea Costa, Guilherme Ximenes, Marco Tulio Guimaraes, Thais Leite and Cassio Segura, respectively.

08:51 EDT Sportradar wins bid for CONMEBOL rights as official global betting partner - The South American Football Confederation has selected Sportradar as the successful bidder for exclusive global audio and video and betting data rights, that will enhance the accessibility and engagement of South American football for a broader global audience. Under the terms of the agreement, the rights encompass the major regional club tournaments organized by CONMEBOL, including the prestigious CONMEBOL Libertadores, CONMEBOL Sudamericana and CONMEBOL Recopa, for the next four seasons. It also marks the first time that domestic AV betting rights for CONMEBOL club competitions are offered in the region.

08:50 EDT Palisade Bio completes patient enrollment in LB1148 dose optimization study - Palisade Bio announced the completion of patient enrollment in its dose optimization study of LB1148. The dose optimization study was designed to generate valuable pharmacokinetic and pharmacodynamic data across multiple doses in healthy adult volunteers and to determine if a different dosing protocol might enhance the risk profile while simultaneously providing efficacy for the development program moving forward.

08:44 EDT Capital Power secures 1 GW supply of ultra-low carbon First Solar modules - First Solar and Capital Power Corporation announced that Capital Power has secured its first order for approximately 1 gigawatt GWDC of responsibly produced, ultra-low carbon thin film solar modules. The Series 6 Plus modules, which will be delivered between 2026 and 2028, will support Capital Power's growing development portfolio. First Solar and Capital Power Corporation announced today that Capital Power has secured its first order for approximately 1 gigawatt GWDC of responsibly produced, ultra-low carbon thin film solar modules. "We are excited to partner with First Solar and its responsibly produced ultra-low carbon solar technology, which supports our solar development pipeline," said Chris Kopecky, Senior Vice President and Chief Legal, Development and Commercial Officer, Capital Power. "First Solar's longstanding investment in domestic supply chains ensures the use of high-quality American solar technology, including products made with significant amounts of domestically sourced content, to power our projects. Together, with our shared commitment to the sustainable and responsible development of the solar industry, we look forward to building on this relationship."

08:39 EDT Invitation Homes and Esusu announce partnership - Invitation Homes and Esusu, a leading financial technology company advancing rent reporting and data solutions for credit building, announced a new partnership to make Esusu's platform for financial health solutions available at no cost to Invitation Homes residents across 80,000+ homes nationwide. This collaboration will provide free positive credit reporting to nearly 200,000 adult residents of Invitation Homes.

08:38 EDT Snail participates in Steam's Summer Sale - Snail announced its participation in the Steam Summer Sale event running from June 29 to July 13. As part of the Summer Sale event, Snail's renowned survival adventure game, ARK: Survival Evolved, has been strategically marked down by 75%, pricing it at a highly competitive $4.99. Alongside ARK, Snail's Old West-themed social deduction title, West Hunt, is also participating in the Summer Sale event. Developed by Tunisia-based indie game studio NewGen in collaboration with Wandering Wizard, Snail's indie sub-label publishing division, West Hunt is offered at a 10% discount, pricing it at just $8.99.

08:36 EDT NewtekOne funded 400 SBA 7(a) loans in Q2 - NewtekOne announced that, through Newtek Bank and residual funding through Newtek Small Business Finance, it funded a record 400 SBA 7(a) loans for the three months ended June 30, 2023, totaling $195.6M, which represents a 21% increase over the number of 7(a) loans funded for the three months ended June 30, 2022. Newtek Bank had $103.2M and $106.1M, respectively, of newly approved and pending closing SBA 7(a) loans in the months of May 2023 and June 2023. The Company is reaffirming its 2023 SBA 7(a) loan funding forecast of $875M, which would represent a 12.8% increase over 2022. Additionally, total closings across all loan products reached $249.1M for the three months ended June 30, 2023. The Company is reiterating its previously issued earnings forecast for the full year 2023 in a range of $1.70 to $2.00 per share. In April 2023, Newtek Bank began funding the SBA 7(a) loan origination pipeline transferred from NSBF. NSBF will remain a non-bank subsidiary of the Company and will continue to service and wind-down its legacy SBA 7(a) loan portfolio in securitization structures. Newtek Bank had approximately $450M in total deposits as of June 30, 2023, which represents a 221% increase in deposits compared to $140M in deposits at National Bank of New York City at December 31, 2022. The Company acquired the NBNYC, and renamed it Newtek Bank, N.A., on January 6, 2023.

08:34 EDT Stronghold Digital Mining reports 225 Bitcoin awarded in June - Stronghold Digital Mining provided the following operational update. During the month of June, Stronghold was awarded approximately 225 Bitcoin through its mining operations, which, when combined with April and May Bitcoin production, equates to over 626 Bitcoin mined during the Q2. This represents approximately 43% growth compared to Bitcoin awards during the Q4 of 2022 and 1% sequential growth compared to the Q1 despite Bitcoin network hash rate growth of 39% and 23% during the same periods, respectively. During June 2023, the Company received and energized the 2,000 Avalon 1346 Bitcoin mining rigs associated with its previously announced Canaan Bitcoin Mining Agreement. The Company continues to actively evaluate incremental opportunities, representing over 1 EH/s, to fill its remaining data center slots. The Company expects to make a decision on the location of a third site for the deployment of the data center equipment during the Q3.

08:32 EDT Bridgeline Digital's solution selected by Designerie - Bridgeline Digital announced that Designerie, a premier importer and distributor of European Designer-Focused Furniture, has chosen HawkSearch, Bridgeline's advanced AI-powered search solution, to drive their ecommerce operations. The premier importer and distributor of European designer-focused furniture has committed to a 36-month agreement with HawkSearch across two of its websites, Designerie and Sika-Design.

08:31 EDT Middleby acquires TERRY Water Treatment Solutions, terms undisclosed - The Middleby Corporation announced the acquisition of TERRY Water Treatment Solutions. The company has a proprietary, environmentally friendly solution to eliminate and prevent scale build up associated with water usage in commercial foodservice equipment including steam, ice and beverage products. TERRY has $5M in annual sales and is based in Chandler, Ariz. "TERRY Citryne is an exceptional, proprietary technology that we are very excited to add to our portfolio. The chemical free, biodegradable solution is proven effective in the removal and prevention of water scale, which is extremely important in commercial foodservice," said Tim FitzGerald, Middleby CEO. "TERRY is currently a partner with several Middleby brands, and our customers have greatly benefitted from their solution with improved equipment performance, reduced maintenance, and consistent high quality of food, ice and beverage." "There is significant potential to expand the TERRY customer base and grow their sales through our current, extensive Middleby product portfolio and customer channels," Mr. FitzGerald concluded

08:27 EDT Guardant360 CDx to receive national reimbursement approval from MHLW - Guardant Health announced that it has been informed it will receive national reimbursement approval from the Japanese Ministry of Health, Labor and Welfare, or MHLW, effective July 24 for its Guardant360 CDx liquid biopsy test for comprehensive genomic profiling, or CGP, for patients with advanced or metastatic solid tumor cancers. This announcement follows the regulatory approval of the Guardant360 CDx test by the MHLW in March 2022.

08:26 EDT enVVeno Medical announces 57 patients enrolled to date in SAVVE study - enVVeno Medical provided an update on enrollment for its ongoing SAVVE U.S. pivotal study for the VenoValve and announced two upcoming investor events. The SAVVE pivotal study is a prospective, non-blinded, single arm, multi-center study of 75 CVI patients. To date, the Company has enrolled 57 patients in the study and expects enrollment to be completed before the end of 2023. "We are very encouraged by the enrollment momentum we have created over the past few months, including the number of new patients currently being considered for SAVVE, and are confident that we will reach full enrollment by the end of the year," commented Robert Berman, CEO. "The new patient enrollment initiatives that we implemented over the course of the study have resulted in significant progress in what is still a somewhat unpredictable and challenging hospital environment."

08:24 EDT Dairy MAX, GCN announce 'Level Unlocked Tournament' - Dairy MAX and Gaming Community Network, a GameSquare Holdings' company, have announced the "Level Unlocked Tournament." This event aims to bring together students and the broader gaming community to educate young gamers on the importance of fueling their body with healthy foods, so they have the energy to play their game. In June, students in Louisiana participated in a video submission challenge for the opportunity to play Madden NFL 23 against NFL player, James Washington, during a match to be broadcasted live on July 19th at 1:00 PM CT. The students were tasked with creating a video that showcased their love for the New Orleans Saints, while sharing how dairy fuels their game.

08:22 EDT Bragg Gaming goes live in Georgia with Adjarabet - Bragg Gaming (BRAG) announced that its proprietary and third-party content is now live in Georgia exclusively to customers of Adjarabet, the country's online gaming operator and a subsidiary of Flutter Entertainment (PDYPY). This furthers Bragg's ongoing expansion into regulated markets across Europe, including Italy, the UK, the Netherlands, Greece, the Czech Republic, Germany and Switzerland.

08:19 EDT Akari Therapeutics appoints Wa'el Hashad to the Board of Directors - Akari Therapeutics announced the appointment of industry veteran Wa'el Hashad to the Akari Board of Directors as an independent director. Hashad, who will serve on both the Audit Committee and Nominating and Governance Committee, brings more than 35 years of biopharmaceutical experience to Akari's Board of Directors with focus on drug approval and commercialization, mergers and acquisitions, and business development. Hashad currently serves as CEO of Longeveron, a U.S. clinical-stage biotechnology company developing regenerative medicines for rare pediatric diseases, aging-related conditions, and unmet medical needs. Previously, he was President and CEO at Avanir Pharmaceuticals. Avanir was acquired by Otsuka Pharmaceutical, and Hashad led the company's full integration into Otsuka's United States operations. Prior to Avanir, Hashad was Executive Vice President and CCO at Seres Therapeutics, where he established the company's launch and marketing strategy for microbiome-based therapies.

08:18 EDT JinkoSolar joins IRENA Coalition for Action - JinkoSolar has officially become a member of the IRENA Coalition for Action, further affirming its dedication to sustainable energy development. Dany Qian, Vice President of JinkoSolar commented: "We are very proud to become a member of the IRENA Coalition. We expect that joining the IRENA Coalition for Action will contribute to enhancing JinkoSolar's industry reputation, fostering business growth and establishing strong partnerships with leading institutions and professionals in global renewable energy development. We believe this will unlock broader opportunities for our development and make a positive contribution to the sustainable advancement of renewable energy globally."

08:17 EDT MDA appoints McDonald as Chief People, Culture, Transformation Officer - MDA (MDALF) announced that Stephanie McDonald has been appointed to the newly created role of Chief People, Culture and Transformation Officer. McDonald will have executive responsibility for MDA's people, culture and transformation agenda to enable the company's strategy and growth, and will report to MDA CEO, Mike Greenley. McDonald most recently served as Chief Human Resources Officer at Ontex (ONXXF).

08:16 EDT Mobiquity announces enhancements for ElecTech, ElecAlytics platforms - Mobiquity Technologies announces new enhancements to its proprietary ElecTech and ElecAlytics platforms, utilizing heuristic models and US districting data to facilitate superior ad curation. The company said, "Driven by the increasingly detailed understanding of user behavior and preferences, Mobiquity Technologies is further evolving digital advertising as it relates to US politics. The new features combine districting data with a myriad of factors such as location, performance metrics, contextual relevance, and sentiment analysis. This integration enables Mobiquity's AI engines to create hyper-segmented and personalized advertisements to better resonate with users on a fundamental level...With the introduction of heuristic data modeling into the mix, the ability to understand, predict, and influence consumer behavior becomes more refined. The AI engines of ElecTech and ElecAlytics can now leverage patterns and trends derived from historical data, offering businesses an opportunity to connect with their prospective customers more effectively."

08:16 EDT Academy Sports opens new store in Peoria, Illinois - Academy Sports + Outdoors announces the opening of its first store in the Peoria area. This marks the second store Academy has opened in 2023. Academy plans to continue its expansion efforts with the goal of opening 13 - 15 stores this year, and a total of 120 to 140 new stores by the end of 2027. "Academy Sports + Outdoors is excited to bring its newest store to the Peoria community as a destination that makes pursuing their sports and outdoors passions easy and affordable," said Sam Johnson, Academy's Executive Vice President of Retail Operations. "Whether you're an angler looking to reel in your next big catch, a grill master preparing for your next backyard party, or a parent shopping for new outfits or sports equipment for the new school year, our low prices and assortment of products encourage customers to have fun."

08:15 EDT Oryzon Genomics reports blinded aggregate safety data from PORTICO trial - Oryzon Genomics reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder. On June 26, 2023, blinded aggregate safety data were reviewed during the recent independent DMC meeting, corresponding to the initial 167 randomized patients. From the blinded data, there were no treatment-related serious adverse events or deaths. An aggregated number of 306 adverse events, affecting 98 patients treated either with vafidemstat or placebo were reported, most of them were mild or moderate, with only 12 reported as severe, in 9 patients, leading to 6 treatment discontinuations or patient withdrawals. The reviewed blinded PORTICO safety data is aligned with aggregated safety data collected from 7 completed vafidemstat clinical trials, in which almost 400 subjects have been treated with the drug. Following the blinded portion of the DMC, the independent DMC members reviewed the unblinded safety data, then provided the recommendation to continue the trial without modifications until full enrollment, which is planned for early Q3 2023. Current data of PORTICO continue to support that vafidemstat is safe and well-tolerated. A predefined independent interim analysis to assess the signal size and futility was done on March 23, 2023 with the data of the first 90 patients that had concluded at least two-thirds of the trial. The outcome of this IA was that PORTICO was not futile and should continue as it is without increasing the number of patients to be recruited. PORTICO is a multicenter, double-blind, randomized, placebo-controlled, Phase IIb trial to evaluate the efficacy and safety of vafidemstat in adult BPD patients. The trial has two primary independent objectives: to reduce agitation and aggression and to produce an overall improvement in BPD severity. The trial is currently actively recruiting patients in Europe and in the US and aims to include 188 patients distributed between two arms. PORTICO has an adaptive design with a pre-defined interim analysis to adjust the sample size in case of excessive variability around the endpoints.

08:14 EDT Big Lots announces execution of $318M sale, leaseback agreement - Big Lots announced that it has entered into a sale and leaseback agreement with affiliates of Blue Owl Capital relating to the company's distribution center in Apple Valley, CA, and 26 owned store locations. The company previously disclosed that it had entered into a Letter of Intent on May 24, 2023, which, in addition to the distribution center and owned stores, contemplated a sale and leaseback of the company's corporate headquarters that has subsequently been excluded from the definitive agreement. The sale and leaseback transaction is scheduled to close within 45 days, subject to continued due diligence, final documentation, and other customary closing conditions. Gross proceeds from the transaction are expected to be $318 million. Net of expenses and taxes, the company expects to receive estimated net proceeds of approximately $310 million. The company intends to use $100 million of the net proceeds from the sale and leaseback transaction to fully pay down its synthetic lease on the Apple Valley distribution center, and to use the remainder of the net proceeds to pay down debt on its asset-based lending revolving credit facility. Commenting on today's announcement, Bruce Thorn, President and CEO of Big Lots stated, "We are pleased to have reached a definitive agreement with Blue Owl for the sale and leaseback of our Apple Valley distribution center and the vast majority of our remaining owned stores. As we discussed on our Q1 earnings call, we are highly focused on ensuring we have plenty of liquidity to get through this period of macroeconomic challenges, and monetizing these assets is a significant step forward in ensuring such liquidity. Blue Owl has been a good partner on our other regional distribution centers, which we sold and leased back in 2020, and we look forward to furthering our relationship through this transaction."

08:13 EDT Bunge, Chevron acquire Argentina seed business Chacraservicios, no terms - Bunge (BG) and Chevron's Renewable Energy Group, a subsidiary of Chevron (CVX), acquired Chacraservicios, based in Argentina, from the Italian-based Adamant Group. This latest investment in novel seeds adds a new oil source in Bunge and Chevron's global supply chains and will help both companies meet the growing demand for lower carbon renewable feedstocks. Terms of transaction were not disclosed. Founded in 2003, Chacraservicios was bought by Adamant Group, which invested through first-stage development of the company. Chacraservicios is focused on the cultivation of Camelina Sativa, a cover crop with high oil content, that benefits farmers, consumers and the environment. Bunge plans to provide Chacraservicios crush tolling and management services. "Agricultural innovation is powering renewable fuels development around the world, and opportunities like this are helping Chevron expand our portfolio of affordable, reliable and lower carbon fuels," said Natalie Merrill, senior vice president for business development with Chevron Renewable Energy Group. "Together with Bunge, Chevron's Renewable Energy Group looks forward to working with the Chacraservicios team on meal and oil processing innovations."

08:13 EDT Canacol Energy says gas sales averaged 186 MMscfpd in June - Canacol Energy provides the following gas sales and operations update. Realized contractual natural gas sales were 186 million standard cubic feet per day for June 2023. As announced on June 6, 2023, the Lulo 2 appraisal well, located on the 100 percent operated VIM21 Exploration and Production contract, encountered 230 feet true vertical depth of net gas pay with average porosity of 20 percent within the primary Cienega de Oro sandstone reservoir. The Lulo 2 well was tied into permanent production and flow tested 24 MMscfpd. As announced on January 23, 2023, the Chimela 1 exploration well, located on the 100% operated VMM45 E&P contract located in the Middle Magdalena Basin, encountered 85 feet of net oil and gas pay within the Tertiary aged Basal Lisama sandstone reservoir. The Basal Lisama sandstone reservoir was perforated in various intervals between 13,625 and 13,694 feet measured depth and tested with a jet pump for 62 hours at an average rate of 353 barrels of oil per day of 23.6 degree API oil. The average water cut during this flow period varied between 2-3% and constant THP of 40 psi was maintained. The well is currently shut in for a build-up period of 20 days. Once the pressure data has been collected, a development plan will be formulated and executed to rapidly commercialize the Chimela discovery. Chimela is located approximately 7 kilometers from the Acordionero field operated by Gran Tierra Energy. The Acordionero field produces approximately 18,600 bopd from the same reservoirs that have proven productive at Chimela. Canacol's near field exploration program includes the successful Lulo discovery, as well as the Pina Norte, Cereza, and Malfadine prospects. The program is targeting exploration prospects located close to the Jobo production facility that can be commercialized very quickly, allowing the Corporation to build productive capacity in order to meet the anticipated high demand for gas associated with the upcoming El Nino phenomena. The Corporation spud the Pina Norte 1 exploration well on its 100% operated VIM21 E&P Contract on June 26, 2023. The well is located approximately 500 meters to the west of the Jobo gas treatment facility and is targeting gas charged reservoirs in the CDO sandstone identical to those encountered at the nearby Lulo discovery. The Corporation anticipates that that well will be drilled, completed, and tied into production within the next 3 weeks. If successful, the Corporation will drill the Pina Norte 2 appraisal well immediately upon completion of the Pina Norte 1 well. The Corporation plans to spud the Cereza 1 exploration well, located on its 100% operated VIM21 E&P contract, in early August. The well is located approximately 500 meters to the north of the Jobo production facility, and it also targeting gas charged sandstones of the CDO reservoir. The well will take approximately 3 weeks to drill, complete, and tie into production. If successful, the Corporation will immediately drill the Cereza 2 appraisal well. The Malfadine 1 exploration well will be the next well to be drilled in the nearfield exploration program, which is located approximately 1.5 kilometers to the northwest of the Jobo production facility. Malfadine 1 is also targeting gas charged reservoirs within the CDO sandstone and will take 3 weeks to drill and complete. If successful, the Corporation will immediately drill the Malfadine 2 and 3 appraisal wells.

08:11 EDT Huadi subsidiary announces investment agreement with Songyang County - Huadi International Group announced that Huadi, a wholly-owned subsidiary of the Company, has entered into an investment agreement with Songyang County Economic Development and Investment Group, a Songyang County local government owned enterprise in Zhejiang Province. The Agreement aims to start an advanced "Future Factory" construction project in the Chishou Industrial Zone of southwestern Zhejiang Province. Pursuant to the Agreement, the factory will occupy approximately 50 acres with a total investment of approximately RMB1B , including fixed asset investments of over RMB620M. HUDI plans to finance the project primarily via its working capital. Huadi Songyang has officially obtained the rights to use the first portion of 26 acres of land from Songyang Economic Development Zone on June 30, 2023, for the construction of the Future Factory project. The Future Factory project is expected to produce 60,000 tons of stainless steel seamless tubes and special alloy steel products annually, including 300 series, 400 series, 600 series, and 800 series. The project will be constructed in two phases, with the first phase building the factory over approximately 26 acres which will commence from December 1, 2023 to November 30, 2026, and the second phase, building the factory over approximately 24 acres which will be completed within 36 months after the land meets the construction requirements. Pursuant to the Agreement, the Songyang County local government has authorized Songyang Group to provide a series of supportive policies for the construction of the Future Factory project, including a total of RMB 15M in infrastructure construction subsidies to be granted to Huadi Songyang upon completion of all fixed asset investments within the agreed period.

08:11 EDT D.R. Horton acquires assets of Truland Homes for $100M cash - D.R. Horton announced the acquisition of Truland Homes. The homebuilding assets of Truland Homes acquired include approximately 263 lots, 155 homes in inventory and 55 homes in sales order backlog. D.R. Horton also acquired 156 lots and control of approximately 400 lots through option contracts from Truland affiliates and 201 lots and control of approximately 260 lots through option contracts from third parties. During calendar 2022, Truland closed 512 homes, or $244M in revenue, with an average home size of approximately 2,340 square feet and an average sales price of $477,000. D.R. Horton expects to pay approximately $100M in cash for the purchase, and the Company plans to combine the Truland operations with its current D.R. Horton platforms in Baldwin County, Alabama and Northwest Florida.

08:10 EDT MiMedx CFO Pete Carlson resigns, Doug Rice to succeed - MiMedx Group announced that it has appointed Doug Rice as the Company's CFO. Pete Carlson, who has served in that role since March 2020, has resigned as CFO. Rice joins MIMEDX after nearly a decade as the CFO of Orthofix Medical.

08:09 EDT Poseida Therapeutics announces FDA clearance of IND for P-CD19CD20-ALLO1 - Poseida Therapeutics (PSTX) announced that the U.S. Food and Drug Administration, FDA, has cleared its Investigational New Drug, IND, application for P-CD19CD20-ALLO1, the Company's first allogeneic dual CAR-T cell product candidate, which targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies and is being developed in partnership with Roche (RHHBY). "We are pleased to receive IND clearance for P-CD19CD20-ALLO1, our third fully allogeneic CAR-T cell product candidate and the second therapy in our partnership with Roche for hematological malignancies that will enter the clinic. We believe this represents the FDA's first known IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20," said Kristin Yarema, Ph.D., President, Cell Therapy at Poseida. "The dual-targeting approach leverages our proprietary non-viral piggyBac(R) DNA Delivery System, which enables expression of two fully functional CAR molecules into T cells from healthy donors for the treatment of B-cell malignancies that may have heterogeneous antigen expression. We believe that targeting both CD19 and CD20 has the potential to overcome the limitations of currently available CD19-directed CAR-T products where antigen escape has been observed as an important resistance mechanism. It has been estimated that up to 40% of cases where B-cell malignancies relapse or are refractory to CD19 targeting autologous CAR-T therapy may involve antigen escape. We look forward to dosing the first patients in this study."

08:08 EDT Triton Funds agrees to invest up to $1M in Asset Entities - Asset Entities has entered into a common stock purchase agreement with investment firm Triton Funds for an investment by Triton in the Company's common equity of up to $1 million. Triton is primarily focused on investments that will have a lasting positive impact on the Millennial generation with a portfolio of both private and public companies. As part of the Agreement, when Asset Entities wishes to sell its common stock, it will first provide Triton with a purchase notice, which sets forth the total number of shares of class B common stock the Company intends to sell. Triton has agreed to purchase up to $1M of the Company's class B common stock through September 30, 2023, subject to the terms and conditions in the Agreement. Asset Entities intends to use any net proceeds from the sale of its common stock to Triton for general corporate and working capital purposes.

08:07 EDT Baker Hughes awarded significant order by MODEC - Baker Hughes (BKR) announced Wednesday it has been awarded a significant order, to be booked in the Q2, by MODEC to supply gas technology equipment for the BM-C-33 project in the Brazilian pre-salt Campos area. The project is developed by Equinor with partners Repsol Sinopec Brasil and Petrobras (PBR). The order comprises of turbomachinery equipment - including LM2500 gas turbine generators and steam turbine generator technology - for a combined cycle power generation solution to be installed in the BM-C-33 FPSO to reduce the project's carbon footprint, as well as process design engineering and balance of plant. For the BM-C-33 project, Equinor and its partners expect the FPSO to be able to achieve a carbon intensity target of less than 6 kg/barrel of oil equivalent (BOE) over the field's lifetime, while the global industry average is 16 kg CO2 per barrel.

08:06 EDT UPS drops 2% in premarket trading after Teamsters talks collapse

08:06 EDT Teamsters union announces 'collapse' of UPS negotiations - The Teamsters union said via Twitter: "Around 4AM, UPS walked away from the bargaining table after presenting an unacceptable offer to the Teamsters that did not address members' needs. The UPS Teamsters Nat'l Negotiating Committee unanimously rejected the package. Following marathon negotiations, UPS refused to give the Teamsters a last, best, and final offer, telling the union the company had nothing more to give." "This multibillion-dollar corporation has plenty to give American workers - they just don't want to," said Teamsters General President Sean M. O'Brien. "UPS had a choice to make, and they have clearly chosen to go down the wrong road." The UPS Teamsters contract covering more than 340,000 full- and part-time workers expires July 31. No additional negotiations are scheduled. Reference Link

08:05 EDT Sabre announces acquisition of Techsembly - Sabre Corporation announced the acquisition of hospitality e-commerce provider Techsembly. Terms of the transaction were not disclosed. "Sabre's agreement with Techsembly reaffirms our position as a leading global hotel commerce and distribution platform in the hospitality industry," said Scott Wilson, president of Sabre Hospitality. "Not only will this acquisition accelerate our product roadmap via Techsembly's marketplace and gift card capabilities, but it also enables us to come together and offer the most robust and effective suite of integrated retailing solutions designed to meet the retailing needs of today's modern hoteliers." As part of the transaction, Sabre will welcome Techsembly's e-commerce experts and developers to the company. Based in the UK with offices in Singapore and Hong Kong, Techsembly enjoys a growing customer base and a strong presence within the luxury hotel segment.

08:03 EDT Dare Bioscience to receive $1.0M in July from Organon under license agreement - Dare Bioscience (DARE) reaffirmed its commitment to the commercial launch of XACIATO, or clindamycin phosphate, vaginal gel, 2% with collaborator Organon (OGN), and announced that Organon will pay Dare $1.0M in July. Under the amended license agreement between Dare and Organon for XACIATO, Organon will pay Dare $1.0M in July and will pay Dare $1.8M upon the first commercial sale of XACIATO. In 2022, Dare received a $10.0M upfront payment from Organon when the license agreement became effective. In addition to the upfront payment and the $2.8M described above, Dare is also eligible to receive additional potential future milestone payments of up to $180.0M and tiered double-digit royalties based on net sales.

08:03 EDT Nikola produced 33 battery trucks in Q2 - Nikola Corporation, via the HYLA brand, announced its quarterly deliveries for its battery-electric truck, with wholesale of 45 trucks and retail of 66 trucks in the quarter ended June 30, 2023. "It is not easy being a pioneer in the zero-emission Class 8 truck space, but we are witnessing a remarkable surge in momentum," said Nikola CEO Michael Lohscheller. "We take great pride in our current achievements and the influx of orders coming in for our soon-to-be-produced hydrogen fuel cell electric truck. I believe there has not been a better time to be at Nikola as we move forward, together."

08:00 EDT Wolfspeed, Renesas sign 10-year silicon carbide wafer supply agreement - Renesas Electronics (RNECY) and Wolfspeed, Inc. (WOLF) announced the execution of a wafer supply agreement and $2 billion deposit by Renesas to secure a 10 year supply commitment of silicon carbide bare and epitaxial wafers from Wolfspeed. The supply of high-quality silicon carbide wafers from Wolfspeed will pave the way for Renesas to scale production of silicon carbide power semiconductors starting in 2025. The decade-long supply agreement calls for Wolfspeed to provide Renesas with 150mm silicon carbide bare and epitaxial wafers scaling in CY2025, reinforcing the companies' vision for an industry-wide transition from silicon to silicon carbide semiconductor power devices. The agreement also anticipates supplying Renesas with 200mm silicon carbide bare and epitaxial wafers after the recently announced John Palmour Manufacturing Center for Silicon Carbide is fully operational.

07:42 EDT ARway.ai announces updates to ARway V2.5 - ARway.ai announced a series of updates with its version 2.5, including AI assisted pathfinding catering to the demand for inclusive, accurate, and user-friendly navigation solutions, new visually stunning navigation path styles, advanced creator tools, and more. The Company also announced the appointment of Nidhi Kumra, CA, CPA, to the Board of Directors and as the Audit Committee Chair.

07:40 EDT Meta Materials appoints Alan Newman as CPO for Authentication - Meta Materials announces the appointment of Mr. Alan Newman as Chief Product Officer for Authentication and Managing Director of the Banknote and Authentication new Business Unit, reporting to META's President and CEO, effective September 5, 2023. Newman has been instrumental in maintaining De La Rue's undisputed status as the paragon of banknote design.

07:37 EDT Chart Industries signs partnership agreement with Chart Industries - Avina Clean Hydrogen announced a partnership agreement with Chart Industries, a global leader in design and manufacture of equipment for the entire hydrogen supply chain. Under the terms of the agreement, Chart will supply their Howden compressors for Avina's state-of-the-art green hydrogen facility in Southern California. The gaseous hydrogen will be compressed and used to decarbonize heavy-duty trucks, marking a significant milestone as the region's first green hydrogen plant. Chart's Howden diaphragm "D" series compressors will enable the safe and efficient transportation of compressed gaseous hydrogen, ensuring its availability as a clean fuel source for heavy-duty trucks throughout Southern California.

07:36 EDT View enters into settlement with the SEC - View announced that it has entered into a settlement with the SEC, resolving the previously disclosed SEC investigation arising from the Company's restated warranty-related accruals in its financial statements. In light of View's self-reporting, prompt remediation and cooperation, the SEC determined not to impose a civil penalty on the Company and there are no ongoing undertakings in connection with the settlement. On May 31, 2022, View issued a Current Report on Form 8-K that disclosed its total restated year-end 2019 warranty liability as $53M and its total restated year-end 2020 warranty liability as $48M. On June 15, 2022, View issued an Annual Report on Form 10-K that marked the completion of the Company's financial restatement.

07:35 EDT CME Group reports June ADV of 23.3M, Q2 ADV 22.9M - CME Group reported its June and Q2 2023 market statistics, reaching an average daily volume of 23.3 million contracts in June, representing the company's second-highest June ADV on record. Q2 ADV was 22.9 million contracts, the second-highest Q2 volume ever.

07:34 EDT Small Pharma announces R&D strategy update to expedite SPL028 program - Small Pharma announced a research and development strategy update, aimed at expediting its clinical program of SPL028, the Company's novel deuterated N, N-dimethyltryptamine compound with multi-layered intellectual property protection. SPL028 is currently dosing in an ongoing Phase I study in healthy volunteers. Preliminary findings from the first two cohorts demonstrate that intravenous SPL028 elicits a psychedelic experience of less than1 hour and is well-tolerated. SPL028 is based on the following target value proposition: Distinct DMT-based therapeutic profile: An extended DMT psychedelic experience of up to ~1 hour may provide efficacy for more patients with depression, and for additional therapeutic indications, compared to native DMT. Additionally, the pharmacokinetic profile of SPL028 may enable optimized dose formulations for different administration routes. Strong commercial proposition: An anticipated short in-clinic treatment offering a rapid and durable antidepressant response, as supported by the SPL026 Phase IIa data, enables the potential for a treatment that is delivered episodically on an "as required" basis, rather than via a fixed treatment regimen. This may maximize convenience for both patients and physicians, as well as provide economic benefits for payers. Robust IP protection: SPL028 has a multi-layered IP portfolio, including Composition of Matter protection in multiple jurisdictions, and protection surrounding related deuterated compounds. Development of the SPL028 program is informed by data from the Company's clinical trials of SPL026, Small Pharma's native DMT compound. The Company showed clear proof-of-concept with SPL026 for the treatment of Major Depressive Disorder in a Phase IIa trial. This was the first placebo-controlled study to demonstrate the clinical efficacy of a DMT-based therapy, indicating a rapid and durable antidepressant response in many patients until at least six months. Further, the PK profiling of IV and intramuscular SPL026 through the Phase I studies has been critical in informing dose selection for the active Phase I SPL028 study. Topline data from the SPL028 Phase I healthy volunteer study is anticipated in Q4 2023. The Company anticipates that the combined data from the SPL026 and SPL028 programs could enable an expedited path to initiating a multi-jurisdiction, multi-site Phase II study in 2024. Accordingly, the Company's protocol for the SPL028 Phase I program includes the option of initiating a Phase Ib patient study of injectable SPL028 in depression. Determination of the optimal development route for SPL028, including the target depression patient population, will be reviewed following the conclusion of the ongoing Phase I studies.

07:31 EDT Duke Energy to sell commercial distributed generation business for $364M - Duke Energy announced it has reached an agreement to sell its commercial distributed generation business to an affiliate of ArcLight Capital Partners, a leading middle market infrastructure investor, for an enterprise value of $364 million, inclusive of non-controlling tax equity interests. Duke Energy expects approximately $259 million of proceeds from this transaction, which is subject to certain customary adjustments and will be received upon closing. In early June, Duke Energy reached a sale agreement for its utility-scale renewables business platform. The company expects to finalize the sales for its utility-scale and distributed generation businesses by the end of 2023 and will utilize the proceeds to strengthen its balance sheet and avoid additional holding company debt issuances associated with these assets. "The sale of our commercial renewables businesses streamlines our portfolio and provides the resources to support the long-term needs of our customers in our growing regulated territories," said Lynn Good, Duke Energy Chair, President and CEO. "Over the next decade, we plan to invest significant amounts of capital to fund the critical energy infrastructure necessary to serve our customers and support our clean energy transition."

07:13 EDT Optex Systems awarded delivery order for LIF assemblies for $3M - Optex Systems Holdings announced it has been awarded a delivery order for Laser Interference Filter, or LIF, assemblies for $3M. The LIF is critical in protecting Night Vision Goggle systems fielded by the U.S. Military. The products will be manufactured at the Applied Optics Center, or AOC, Division of Optex Systems. With this order, the current Optex backlog is in excess of $40.5M.

07:10 EDT Transcode remains 'steadfast' on advancing pipeline, exploring collaborations - In a letter to shareholders, Transcode CEO R. Michael Dudley said, "I want to express the optimism that permeates the management, board, and staff of TransCode as we navigate the ever-evolving oncology field and venture into the clinic with our lead candidate to treat metastatic disease. This optimism is also reflected by the fact that members of management have purchased shares of the Company in the open market in the past two weeks. I am delighted to inform you about the accomplishments and advancements we have attained at TransCode following our initial public offering in July 2021. Your unwavering support and trust in our mission have been of immeasurable value, and I am grateful for your steadfast dedication. In our dedicated pursuit to transform the treatment of cancer, we believe TransCode Therapeutics has made significant strides in research, innovation, and clinical development. Our team of scientists, researchers, and professionals have tirelessly worked towards this pursuit, and I am delighted to report that we have achieved several noteworthy milestones. One of our achievements this year has been the successful advancement of our lead therapeutic candidate, TTX-MC138, utilizing our proprietary targeted therapeutic delivery platform. TTX-MC138 is focused on treating metastatic cancer, as characterized by the spread of a tumor from the organ of origin to other parts of the body, which is believed to be the cause of approximately 90% of all cancer deaths totaling over nine million per year worldwide. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of metastatic cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and many others. We have observed significant tumor regression and durable responses in multiple animal models, which we believe support the therapeutic potential of TTX-MC138. In December 2022, we received approval from the FDA to proceed with our first-in-human clinical trial. In April 2023, we received institutional review board approval from Dana Farber Cancer Center in Boston, MA, to enroll and dose patients in our Phase 0 trial, which we expect to commence shortly. In parallel, we are completing IND enabling studies for our planned Phase I/II clinical trial, for which we hope to file an IND application with FDA later this year to initiate our clinical trial to treat cancer patients...As we look ahead, we remain steadfast in our commitment to advancing our pipeline, expanding collaborations, and exploring new therapeutic avenues. Our goal is to continue pushing the boundaries of what is possible in the field of oncology, bringing hope to patients and transforming the treatment landscape. We are hopeful that our targeted therapeutic delivery platform, exemplified by the progress of TTX-MC138, will play a pivotal role in realizing this vision."

07:06 EDT Medicenna Therapeutics extends period to exercise certain warrants - Medicenna Therapeutics has received conditional approval from the Toronto Stock Exchange to extend the expiry date of a total of 1,549,052 outstanding common share purchase warrants of the Company originally issued on October 17, 2019 as part of a public offering of units of the Company. Each warrant is exercisable for a common share of the Company at a price of $1.75 per Common Share and set to expire on July 17, 2023. The Company has extended the expiry date of such Warrants until October 17, 2024, with such extension being effective on July 17, 2023. All other terms of the Warrants, including the exercise price, remain unchanged. None of the outstanding warrants are held by insiders.

07:04 EDT BioCardia completes submission of CardiAMP Cell Therapy System in Japan - BioCardia announces it completed its submission of the CardiAMP Cell Therapy System to Japan's Pharmaceutical and Medical Device Agency, or PMDA, towards approval for the indication of ischemic heart failure with reduced ejection fraction, or HFrEF. The formal consultation with PMDA to review the submission is anticipated in approximately three months and will be BioCardia's third consultation with PMDA.

07:03 EDT FCC issues Telesat Phase II certification of accelerated relocation order - Telesat announced that the Wireless Telecommunications Bureau of the U.S. Federal Communications Commission has validated Telesat's Phase II certification of accelerated C-band clearing activities in the 3.7 GHz band. With this order, the FCC confirms that Telesat has completed all requirements for relocating customers from the 3700-3820 MHz band in the contiguous U.S. along with all required Earth station equipment modifications. Telesat fulfilled the Phase II relocation requirements six months in advance of the December 2023 deadline, and is now eligible to receive its second accelerated relocation payment of nearly $260M, expected by October 2023. Telesat has already received its Phase I clearing payments totaling $84.8M.

07:02 EDT C4 Therapeutics announces FDA cleared IND application for CFT8919 - C4 Therapeutics, or C4T, announced that the FDA has cleared the company's investigational new drug, or IND, application for CFT8919, an orally bioavailable BiDAC degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer, or NSCLC, patients. This milestone marks C4T's fourth IND clearance from its proprietary TORPEDO platform. In May 2023, C4T and Betta Pharmaceuticals entered into an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China, including Hong Kong SAR, Macau SAR and Taiwan.

07:01 EDT Callon Petroleum announces closing of Delaware Basin acquisition - Callon Petroleum announced that it closed its previously announced acquisition of Delaware Basin assets from Percussion Petroleum Operating II and the sale of its Eagle Ford assets to Ridgemar Energy Operating on July 3, 2023. "We are excited to announce the completion of another important strategic move for Callon and its shareholders. Through these two transactions, we have created a singular focus on the Permian Basin, reduced our absolute debt position, and kicked off a shareholder return plan," said Joe Gatto, President and CEO. "The bolt-on Percussion transaction improves our Delaware inventory depth and also lowers our cost structure. I would like to thank everyone at Callon, Percussion, and Ridgemar for their efforts to close these transactions."

06:51 EDT Ring Energy actively pursuing sale of operated assets in New Mexico - As part of Ring's continued focus on maximizing cash flow generation and improving its balance sheet, the Company is actively pursuing the sale of its operated assets in New Mexico. Ring is consolidating its development efforts in its core operating areas in Texas. The New Mexico assets for sale include approximately 5,700 gross acres and currently produce approximately 300 net Boe/d.

06:48 EDT Perfect Corp. launches AI Fashion feature for YouCam Makeup app - Perfect Corp (PERF) announced the launch of its AI Fashion feature for its YouCam Makeup app. The company said, "The AI Fashion tool, powered by generative AI, provides users with a personalized digital fashion stylist - revolutionizing the way users experiment with their clothing, hairstyle and makeup through AI-generated images with a range of fashion looks and styles. With the power of advanced Artificial Intelligence, this innovative feature empowers users to completely transform their style and create stunning virtual makeovers and style looks with just a few taps. With just a personal device, users can now effortlessly explore limitless fashion possibilities and achieve their desired style looks like never before."

06:36 EDT KalVista reports inducement grants under Nasdaq listing rule - KalVista Pharmaceuticals announced that the compensation committee of KalVista's board of directors granted two newly-hired employees inducement options to purchase an aggregate of 13,000 shares of KalVista common stock on July 3, 2023 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.04 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

06:35 EDT Leicester City FC, JD Sports colluded to restrict competition, says U.K.'s CMA - As part of an investigation which began in September 2021, the Competition and Markets Authority has issued a statement of objections, which sets out its provisional assessment of the case. This follows admissions by Leicester City FC and JD Sports that they broke competition law by entering into an arrangement which limited competition in the sales of Leicester City-branded clothing, including replica kit, in the UK. Leicester City FC and its parent companies have, under the settlement procedure, admitted Leicester City FC's participation in the alleged arrangement. They have agreed to pay a fine under the CMA's settlement policy of a maximum GBP 880k. The CMA said: "JD Sports reported the illegal conduct and admitted its participation in the alleged conduct by way of a leniency application. It will not receive a fine provided that it continues to co-operate and to comply with the other conditions of the CMA's leniency policy." Reference Link

06:32 EDT Ault regains compliance with the NYSE - Ault Alliance announced that on July 3 the NYSE American notified AAI that the Company has successfully regained compliance with the NYSE American's continued listing standards related to price per share set forth in Section 1003 of the NYSE American Company Guide.

06:20 EDT Incyte UK announces that MHRA granted authorization for Opzelura cream - Incyte Biosciences UK announced that the Medicines and Healthcare Products Regulatory Agency, or MHRA, has granted marketing authorisation for Opzelura, or ruxolitinib, cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Opzelura is the first and only approved treatment in the UK to offer eligible patients with non-segmental vitiligo support for repigmentation. The MHRA decision follows the European Commission approval earlier in April. Vitiligo is a chronic autoimmune disease in which areas of skin depigment or lose their colour due the progressive destruction of pigment-producing cells known as melanocytes. The MHRA decision is based on data from two pivotal Phase 3 clinical trials, evaluating the efficacy and safety of ruxolitinib cream versus vehicle in more than 600 people with non-segmental vitiligo, age 12 and older7. Results from the TRuE-V program showed that treatment with ruxolitinib cream resulted in significant improvements in facial and total body repigmentation versus vehicle as shown by the number of patients reaching the facial and total body Vitiligo Area Scoring Index endpoints at Week 24 compared to vehicle and in an open-label extension at Week 527. Results at Week 24, which were consistent across both studies, showed that 29.8% and 30.9% of patients treated with ruxolitinib cream achieved greater than or equal to75% improvement from baseline in the facial Vitiligo Area Scoring Index, the primary endpoint, compared to 7.4% and 11.4% of patients treated with vehicle in TRuE-V1 and TRuE-V2, respectively7.

06:18 EDT Patterson-UTI to acquire Ulterra for $370M in cash, 34.9M shares - Patterson-UTI Energy (PTEN) has entered into a definitive agreement to acquire Ulterra Drilling Technologies for consideration of $370M of cash and 34.9M shares of Patterson-UTI common stock. Founded in 2005 and headquartered in Fort Worth, Texas, privately-owned Ulterra designs, manufactures, sells and rents PDC drill bits. With a global footprint, Ulterra supports customers in over 30 countries with sales, manufacturing, and repair facilities throughout North and South America, the Middle East, and Asia. In North America, Ulterra is a leading provider of PDC drill bits, with operations across the most active basins in the United States and Canada. Under the terms of the transaction, Patterson-UTI will acquire Ulterra Drilling Technologies, L.P. from affiliates of Blackstone Energy Partners (BX) on a debt-free basis for aggregate consideration of $370M of cash and 34.9M shares of Patterson-UTI common stock. Patterson-UTI intends to fund the $370M cash consideration using cash on hand and Patterson-UTI's revolving line of credit. In connection with the transaction, Blackstone has entered into a voting agreement with NexTier Oilfield Solutions (NEX), whereby Blackstone will vote the shares of Patterson-UTI issued in the transaction and held by the stockholder at the time of the Patterson-UTI special meeting in a manner to facilitate the consummation of the merger between Patterson-UTI and NexTier. The pending transaction, which is expected to close in the third quarter of 2023, is subject to customary closing conditions and receipt of required regulatory approvals, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Act. The Ulterra business will continue to operate under the name Ulterra, and its headquarters will remain in Fort Worth, Texas.

06:16 EDT Monroe Capital completes acquisition of Horizon Technology - Monroe Capital (MRCC) announced it has completed the acquisition of Horizon Technology Finance Management, a market leader in venture debt lending. Horizon is the investment adviser to Horizon Technology Finance Corporation (HRZN). Horizon is a leading investment manager of venture debt products for high-growth companies in the technology, life sciences, healthcare information and services, and sustainability industries. The acquisition of Horizon augments Monroe Capital's existing platform with an experienced investment team and distinguished track record across multiple market cycles. Horizon's current management team and investment professionals of Horizon are continuing to serve as officers and senior management of the company.

06:14 EDT Digihost Bitcoin reports 70 Bitcoin mined in June - Digihost Technology provided an update on its operational sustainability initiatives along with delivering unaudited comparative Bitcoin production results for the month ended June 30 combined with an operations update. The Company is pleased to report the following Green Energy milestones: The New York Independent System Operator Power Trends 2023 reports that "Upstate New York" production is now 93% emissions free; Six months earlier than anticipated, the Company's East Delevan facility is now the anchor subscriber to a community solar project in National Grid territory that generates more than 5MW's of renewable energy into the National Grid system; Digihost entered into an additional NYISO-level curtailment program that demands fast acting curtailment of load. The company mined approximately 70 BTC. Of the 70 BTC mined, approximately 54 were self-mined with the remainder under JV hosting partnerships. Production of BTC mined is expected to continue to ramp up over the remainder of the year as the Company finalizes the infrastructure setup at its most recently acquired site. Infrastructure installation has been completed at the Company's other two sites. The Company held cash, BTC and cash deposits of approximately $2.3M as of June 30 which was in line with Digihost's cash and crypto holdings of $2.7M as of May 31. During the month of June, the Company spent approximately $400,000 on capital expenditure and mining infrastructure support equipment. Digihost continues to monitor its capital expenditures closely with self-funding to avoid equity dilution for its shareholders. Consistent with management's ongoing commitment to avoid equity dilution for its shareholders, the Company has continued to monetize a portion of its BTC production to fully fund its energy costs. As a result of the Company's recent site acquisition in Q1 2023, Digihost's consolidated operating capacity across its three sites has increased to approximately 100MW, representing approximately 2 EH of computing power.

06:06 EDT Brookfield Reinsurance to acquire American Equity in $4.3B transaction - Brookfield Reinsurance (BNRE) and American Equity Investment Life Holding Company have entered into a definitive agreement whereby Brookfield Reinsurance will acquire all of the outstanding shares of common stock of AEL it does not already own in a cash and stock transaction that values AEL at approximately $4.3B. As part of the agreement, each AEL shareholder will receive $55.00 per AEL share, consisting of $38.85 in cash and 0.49707 of a Brookfield Asset Management (BAM) class A limited voting share having a value equal to $16.15, subject to adjustment in certain circumstances as described below. The Merger Consideration of $55.00 per share represents a 35% premium to AEL's undisturbed closing share price on June 23, 2023 and a 42% premium to AEL's 90-day VWAP as of such date. Following closing, Brookfield Reinsurance expects to maintain AEL's headquarters in Des Moines, Iowa and that growth in the AEL platform over time should increase net jobs in Iowa. Brookfield Reinsurance also looks forward to supporting the greater Des Moines area, including through maintaining AEL's existing charitable contributions and through Brookfield's broader charitable foundation and other charitable initiatives. Brookfield Reinsurance also intends to continue AEL's focus on alternative asset strategies and expects BAM will manage a significant portion of AEL's assets. As a result, AEL will gain access to BAM's leading direct origination platforms and asset management capabilities while maintaining its current high-quality bias and investment grade focus. If based on the 10-day VWAP of the BAM Shares, the BAM Shares are trading at a price such that the aggregate consideration per AEL share would be less than $54.00 per share, the number of BAM Shares delivered for each AEL Share will be increased such that the value of the aggregate consideration delivered for each AEL Share will equal $54.00 and Brookfield Reinsurance will have the option to pay cash in lieu of some or all of the share portion of the Merger Consideration. In the event that the BAM Final Stock Price would result in the aggregate Merger Consideration per AEL Share being greater than $56.50, the number of BAM Shares delivered for each AEL Share will be decreased such that the value of the aggregate consideration delivered for each AEL Share will equal $56.50. Brookfield Reinsurance intends to acquire from Brookfield Corporation (BN) the BAM Shares required to satisfy the non-cash consideration offered to AEL shareholders. Subject to this occurring, BAM's public float will increase by approximately 10%, which is strategically important as BAM continues to broaden its shareholder base and BN's interest in BAM will decrease from 75% to approximately 73%. Accordingly, there will be no net new issuance of shares of BAM, BN or Brookfield Reinsurance and no dilution to BAM, BN or Brookfield Reinsurance shareholders as a result of this transaction. The cash portion will be funded from excess liquidity within Brookfield Reinsurance. The transaction is not subject to any financing condition or contingency. Each of Brookfield Reinsurance's and AEL's boards of directors unanimously approved the merger agreement. The merger is expected to close in the first half of 2024, subject to approval by AEL shareholders and other closing conditions customary for a transaction of this type, including receipt of insurance regulatory approvals in relevant jurisdictions and the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Upon the closing of the proposed transaction, AEL Shares will be delisted from the New York Stock Exchange and shares of AEL's series A noncumulative preferred stock and series B preferred stock will remain listed on the New York Stock Exchange. Under the terms of the merger agreement, AEL has agreed to suspend the payment of dividends on its common stock through the closing of the transaction, unless the transaction does not close by April 4, 2024, in which case the AEL Board may decide to reinstate the payment of dividends on its common stock.

06:04 EDT HSBC launchs its Global Private Banking business in India - HSBC has launched its Global Private Banking, or GPB, business in India to serve high-net-worth, or HNW, and ultra-high-net-worth, or UHNW, professionals, entrepreneurs and their families. The new business is aimed at clients with investable assets of more than $2M. India surpassed the UK as the world's fifth largest economy in 2022 and is expected to overtake Japan and Germany by 2027-281. HSBC Group has also been strengthening its presence in India including acquiring L&T Investment Management Limited in 2022, now called HSBC Mutual Fund, and enhancing digital, payment, lending and international banking services, and providing life insurance services through its joint venture, Canara HSBC Life.

05:35 EDT Nutex Health opens new microhospital in Louisiana - Nutex Health announced the opening of its newest microhospital, Covington Trace ER & Hospital, in Mandeville, Louisiana. The hospital is conveniently located at 4107 LA-59, on the Southeast corner of Interstate 12 and Highway 59. The new 21,000 square foot facility is open 24/7, 365 days a year, and includes an emergency room with eight private exam rooms, 10 private inpatient beds, as well as in-house imaging, pharmacy, and laboratory services.

05:25 EDT Dexcom announces Health Canada approval for Dexcom G7 - Dexcom announced that Health Canada has approved the next-generation Dexcom G7 Continuous Glucose Monitoring System for people with all types of diabetes, ages two years and older.

05:19 EDT Absolute Software obtains final order from Supreme Court for acquisition - Absolute Software announced that the company has obtained a final order from the Supreme Court of British Columbia approving the previously announced acquisition of all of the outstanding shares of Absolute by 1414364 B.C. LTD., an affiliate of Crosspoint by way of a statutory plan of arrangement. Under the terms of the arrangement, Absolute's shareholders will receive $11.50 for each share held. The arrangement remains subject to customary closing conditions, including approval under Australia's Foreign Acquisitions and Takeovers Act 1975, and is expected to close during the second half of 2023. Following completion of the Transaction, the common shares of Absolute are expected to be delisted from the Toronto Stock Exchange and the Nasdaq Global Market. An application will also be made for the company to cease to be a reporting issuer in the applicable jurisdictions following completion of the arrangement. The company will also deregister the shares under the U.S. Securities Exchange Act of 1934, as amended.

05:09 EDT Vertex Pharmaceuticals granted approval for label extension of Orkambi - Vertex Pharmaceuticals announced that the European Commission has granted approval for the label extension of Orkambi for the treatment of children with cystic fibrosis, or CF, ages one to less than two years old who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene, the most common form of the disease.